{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:10:03Z","timestamp":1795090203703,"version":"4.10.2"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA05557-02"],"award-info":[{"award-number":["DA05557-02"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA037109-10"],"award-info":[{"award-number":["DA037109-10"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.drugalcdep.2025.112701","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:06:01Z","timestamp":1746723961000},"page":"112701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing"],"prefix":"10.1016","volume":"272","author":[{"given":"Katherine","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9278-1830","authenticated-orcid":false,"given":"Kirsten E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.112701_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12016-016-8536-9","article-title":"The basis of structure\/function claims of nutraceuticals","volume":"51","author":"Borchers","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112701_bib2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1360-0443.2008.02209.x","article-title":"Self-treatment of opioid withdrawal using Kratom (Mitragynia Speciosa Korth","volume":"103","author":"Boyer","year":"2008","journal-title":"Addiction"},{"issue":"April","key":"10.1016\/j.drugalcdep.2025.112701_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jep.2017.03.020","article-title":"A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna Korth: implications for products sold as Kratom","volume":"202","author":"Brown","year":"2017","journal-title":"J. Ethnopharmacol."},{"issue":"22","key":"10.1016\/j.drugalcdep.2025.112701_bib4","doi-asserted-by":"crossref","first-page":"16553","DOI":"10.1021\/acs.jmedchem.1c01111","article-title":"Oxidative metabolism as a modulator of Kratom\u2019s biological actions","volume":"64","author":"Chakraborty","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drugalcdep.2025.112701_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/968786","article-title":"Following \u2018the Roots\u2019 of Kratom ( Mitragyna Speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western Countries","volume":"2015","author":"Cinosi","year":"2015","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.drugalcdep.2025.112701_bib6","article-title":"Not all Kratom is equal: the important distinction between Native leaf and extract products","author":"Grundmann","year":"2023","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112701_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/adb.12639","article-title":"Abuse liability and therapeutic potential of the Mitragyna Speciosa (Kratom) alkaloids mitragynine and 7-hydroxymitragynine","volume":"24","author":"Hemby","year":"2019","journal-title":"Addict. Biol."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112701_bib8","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/acsptsci.0c00075","article-title":"Metabolism of a Kratom alkaloid metabolite in human plasma increases its opioid potency and efficacy","volume":"3","author":"Kamble","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"21","key":"10.1016\/j.drugalcdep.2025.112701_bib9","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1021\/jacs.6b00360","article-title":"Synthetic and receptor signaling explorations of the Mitragyna Alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators","volume":"138","author":"Kruegel","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112701_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","article-title":"7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects","volume":"5","author":"Kruegel","year":"2019","journal-title":"ACS Cent. Sci."},{"issue":"18","key":"10.1016\/j.drugalcdep.2025.112701_bib11","doi-asserted-by":"crossref","first-page":"13510","DOI":"10.1021\/acs.jmedchem.1c00726","article-title":"Activity of Mitragyna Speciosa (\u2018Kratom\u2019) Alkaloids at Serotonin Receptors","volume":"64","author":"Le\u00f3n","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112701_bib12","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.jemermed.2022.02.004","article-title":"Acute renal insufficiency associated with consumption of hydrocodone-and morphine-adulterated kratom (Mitragyna Speciosa)","volume":"63","author":"LeSaint","year":"2022","journal-title":"J. Emerg. Med."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112701_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13318-021-00684-2","article-title":"Oral pharmacokinetics in beagle dogs of the mitragynine metabolite, 7-hydroxymitragynine","volume":"46","author":"Maxwell","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112701_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.122.001192","article-title":"Interactive effects of \u039c-opioid and adrenergic-\u03912 receptor agonists in rats: pharmacological investigation of the primary Kratom alkaloid mitragynine and its metabolite 7-hydroxymitragynine","volume":"383","author":"Obeng","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112701_bib15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jat\/bkae099","article-title":"Postmortem distribution of mitragynine and 7-hydroxymitragynine in 51 cases","volume":"49","author":"Osawa","year":"2025","journal-title":"J. Anal. Toxicol."},{"issue":"06","key":"10.1016\/j.drugalcdep.2025.112701_bib16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1055\/s-2006-959578","article-title":"A new indole Alkaloid, 7 \u03b1-Hydroxy-7 H -Mitragynine, from Mitragyna Speciosa in Thailand","volume":"60","author":"Ponglux","year":"1994","journal-title":"Planta Med."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112701_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41589-022-01208-y","article-title":"Insights into distinct signaling profiles of the \u00b5OR activated by diverse agonists","volume":"19","author":"Qu","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drugalcdep.2025.112701_bib18","unstructured":"Sharma, Abhisheak. 2025. \u201cCharacterization and Safety Profile of Products Labeled as 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl.\u201d Presented at the International Kratom Symposium, Lake Nona, Orlando, Florida, USA, February 5."},{"issue":"September","key":"10.1016\/j.drugalcdep.2025.112701_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.brainresbull.2016.05.004","article-title":"Traditional and non-traditional uses of mitragynine (Kratom): a survey of the literature","volume":"126","author":"Singh","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112701_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/add.16728","article-title":"The rise of novel, semi-synthetic 7-hydroxymitragnine products","volume":"120","author":"Smith","year":"2025","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112701_bib21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/00952990.2022.2083967","article-title":"Kratom use as more than a self-treatment","volume":"48","author":"Smith","year":"2022","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"May","key":"10.1016\/j.drugalcdep.2025.112701_bib22","article-title":"Examining the paradoxical effects of Kratom: a narrative inquiry","volume":"14","author":"Smith","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112701_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.53401","article-title":"Ecological momentary assessment of self-reported Kratom use, effects, and motivations among US adults","volume":"7","author":"Smith","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"ember","key":"10.1016\/j.drugalcdep.2025.112701_bib24","article-title":"Time course of kratom effects via ecological momentary assessment, by product type, dose amount, and assayed alkaloid content","volume":"264","author":"Smith","year":"2024","journal-title":"Drug Alcohol Depend."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112701_bib25","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jps.2600630916","article-title":"Metabolites of mitragynine","volume":"63","author":"Zarembo","year":"1974","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112701_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259326","article-title":"Plant growth and phytoactive alkaloid synthesis in Kratom [Mitragyna Speciosa (Korth.)] in response to varying radiance. Edited by Xiao Guo","volume":"17","author":"Zhang","year":"2022","journal-title":"PLoS One"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:04:40Z","timestamp":1774530280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625001541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"alternative-id":["S0376871625001541"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112701","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112701"}}